This site is intended for U.S. Healthcare Professionals.

Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve.
Click here to learn how we are responding.

Frequently Asked Questions

12 years of age and older

FDA Approved for: Individuals 12 years of age and older, DILUTE BEFORE USE (Purple Cap) AND DO NOT DILUTE (Gray Cap) presentations.

COMIRNATY® (COVID-19 Vaccine, mRNA): FDA APPROVED FOR INDIVIDUALS 12 YEARS OF AGE AND OLDER AS A TWO-DOSE PRIMARY SERIES1,2

In individuals 12 years of age and older, COMIRNATY® (COVID-19 Vaccine, mRNA)* has been approved as a 2-dose primary series for active immunization to prevent COVID-19 caused by SARS-CoV-2.


Pfizer-BioNTech COVID-19 Vaccine: FDA AUTHORIZED FOR EMERGENCY USE3-6

Emergency uses of the vaccine have not been approved or licensed by FDA, but have been authorized by FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19 in individuals 6 months of age and older. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.

*When prepared according to their respective instructions for use, the FDA-approved COMIRNATY® (COVID-19Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine for individuals 12 years of age and older can be used interchangeably without presenting any safety or effectiveness concerns.

Because of the potential for vaccine administration errors, including dosing errors, COMIRNATY® (COVID-19 Vaccine, mRNA) and the Pfizer-BioNTech COVID-19 Vaccine presentations should only be used for the ages specified on the vial labels, cartons, or the respective age-based Fact Sheet. The information in the Fact Sheets supersedes the information printed on the vial labels and cartons.

For vaccination of individuals advancing into the next age group (4 years of age turning 5 years of age or 11 years of age turning 12 years of age) between any primary series dose, refer to the respective age-based Fact Sheet for Healthcare Providers for instructions for administration.

Questions and Answers About COMIRNATY® (COVID-19 Vaccine, mRNA) and Pfizer-BioNTech COVID-19 Vaccine for Ages 12 Years and Older

Go to Section

Approval and
Authorization Status

Access to Vaccine Supply

Diluent

Dosing and Administration

Storage and Stability

Dry Ice

Thermal Shipping Container

Ensuring Authenticity

Approval and Authorization Status

OPEN ALL

CLOSE ALL

What does FDA approval mean?
When the FDA approves a vaccine, it means they have determined, based on substantial evidence, that it is effective for its intended use, and that its benefits outweigh its risks when used according to the product’s approved labeling.7
What is the difference between FDA approval and an Emergency Use Authorization (EUA)?

When the FDA approves a vaccine, it means they have determined, based on substantial evidence, that it is effective for its intended use, and that its benefits outweigh its risks when used according to the product’s approved labeling.7

According to the FDA, “During a public health emergency, the FDA can use its Emergency Use Authorization (EUA) authority to allow the use of unapproved medical products, or unapproved uses of approved medical products, to diagnose, treat, or prevent serious or life-threatening diseases when certain criteria are met, including that there are no adequate, approved, and available alternatives."7

For whom is the vaccine FDA approved or authorized?

COMIRNATY® (COVID-19 Vaccine, mRNA) is a vaccine that has been approved as a two-dose primary series for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older.1,2 The Pfizer-BioNTech COVID-19 Vaccine has received Emergency Use Authorization (EUA) from the FDA to prevent COVID-19 in individuals 6 months of age and older.3,4 Please see below for a list of authorized emergency uses.

When prepared according to their respective instructions for use, the FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine for individuals 12 years of age and older can be used interchangeably without presenting any safety or effectiveness concerns.

Because of the potential for vaccine administration errors, including dosing errors, COMIRNATY® (COVID-19 Vaccine, mRNA) and the Pfizer-BioNTech COVID-19 Vaccine presentations should only be used for the ages specified on the vial labels, cartons or the respective age-based Fact Sheet. The information in the Fact Sheets supersedes the information printed on the vial labels and cartons.

For vaccination of individuals advancing into the next age group (4 years of age turning 5 years of age or 11 years of age turning 12 years of age) between any primary series dose, refer to the respective age-based Fact Sheet for Healthcare Providers for instructions for administration.

COMIRNATY® (COVID-19 Vaccine, mRNA) is authorized for emergency use to provide:
  • a third 30 mcg modRNA primary series dose to individuals 12 years of age and older with certain kinds of immunocompromise
  • a first 30 mcg modRNA booster dose to individuals 12 years of age and older who have completed a primary series with Pfizer-BioNTech COVID-19 Vaccine or COMIRNATY® (COVID-19 Vaccine, mRNA)
  • a first 30 mcg modRNA booster dose to individuals 18 years of age and older who have completed primary vaccination with another authorized or approved COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination
  • a second 30 mcg modRNA booster dose to individuals 50 years of age and older who have received a first booster dose of any authorized or approved COVID-19 vaccine
  • a second 30 mcg modRNA booster dose to individuals 12 years of age and older with certain kinds of immunocompromise and who have received a first booster dose of any authorized or approved COVID-19 vaccine
The Pfizer-BioNTech COVID-19 Vaccine has received Emergency Use Authorization (EUA) from FDA to prevent COVID-19 to provide:
  • a 3-dose 3 mcg modRNA primary series to individuals 6 months through 4 years of age
  • a 2-dose 10 mcg modRNA primary series to individuals 5 through 11 years of age
  • a 2-dose 30 mcg modRNA primary series to individuals 12 years of age and older
  • a third 10 mcg modRNA primary series dose to individuals 5 through 11 years of age with certain kinds of immunocompromise
  • a third 30 mcg modRNA primary series dose to individuals 12 years of age and older with certain kinds of immunocompromise
  • a single 10 mcg modRNA booster dose to individuals 5 through 11 years of age who have completed a primary series with Pfizer-BioNTech COVID-19 Vaccine
  • a first 30 mcg modRNA booster dose to individuals 12 years of age and older who have completed a primary series with Pfizer-BioNTech COVID-19 Vaccine or COMIRNATY® (COVID-19 Vaccine, mRNA)
  • a first 30 mcg modRNA booster dose to individuals 18 years of age and older who have completed primary vaccination with another authorized or approved COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination
  • a second 30 mcg modRNA booster dose to individuals 50 years of age and older who have received a first booster dose of any authorized or approved COVID-19 vaccine
  • a second 30 mcg modRNA booster dose to individuals 12 years of age and older with certain kinds of immunocompromise and who have received a first booster dose of any authorized or approved COVID-19 vaccine
Certain kinds of immunocompromise refers to individuals who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.

For information on booster dose eligibility in individuals 5 through 11 years of age, please refer to EUA Fact Sheet for Vaccination Providers (5 Through 11 Years), DILUTE BEFORE USE, Orange Cap , or click here.

For information on vaccine eligibility in individuals 6 months through 4 years of age, please refer to EUA Fact Sheet for Vaccination Providers (6 Months Through 4 Years), DILUTE BEFORE USE, Maroon Cap.
What is COMIRNATY®?
COMIRNATY® is the brand name for an FDA-approved vaccine, indicated in individuals 12 years of age and older, to prevent COVID-19 caused by SARS-CoV-2. When a medical product receives FDA approval, a brand name for the product is also approved by the FDA.8
For which age groups has the vaccine received FDA approval?
COMIRNATY® (COVID-19 Vaccine, mRNA) is FDA approved for use as a 2-dose primary series for the prevention of COVID-19 in individuals 12 years of age and older.1,2
In the clinical trial, what was the efficacy & safety of the vaccine?
Please see the Emergency Use Authorization (EUA) Fact Sheet for Vaccination Providers (12 years of age and older), DILUTE BEFORE USE, Purple Cap and the Emergency Use Authorization (EUA) Fact Sheet for Vaccination Providers (12 years of age and older), DO NOT DILUTE, Gray Cap to see the clinical trial design, safety, and efficacy information.

Access to Vaccine Supply

OPEN ALL

CLOSE ALL

How can I order the vaccine for my practice, office, or hospital?
The US Government will oversee the distribution and coordination. State, local, and tribal authorities will be responsible for the allocation of doses to populations in their jurisdictions. The CDC will use its current centralized distribution contract to fulfill orders for most COVID-19 vaccine products and associated ancillary supplies.10
Whom can I call with product questions?
For product questions, please call 1-877-829-2619 .
What is the Current Procedural Terminology (CPT) code?

The CPT code for COMIRNATY® COVID-19 Vaccine, mRNA (12 years of age and older) DILUTE BEFORE USE, Purple Cap and the Pfizer-BioNTech COVID-19 Vaccine (12 years of age and older) DILUTE BEFORE USE, Purple Cap presentation is 91300. The administrative code is 0001A for the first dose, 0002A for the second dose, 0003A for the third dose, and 0004A for the first and second booster doses.

The CPT code for COMIRNATY® COVID-19 Vaccine, mRNA (12 years of age and older) DO NOT DILUTE, Gray Cap and the Pfizer-BioNTech COVID-19 Vaccine (12 years of age and older) DO NOT DILUTE, Gray Cap presentation is 91305. The administrative code is 0051A for the first dose, 0052A for the second dose, 0053A for the third dose, and 0054A for the first and second booster doses.
What is the cost of the vaccine?
The federal government has contracted with McKesson for purposes of vaccine distribution, such that no American will be charged for either the COVID-19 vaccine or its distribution.10
Who will provide the syringes and needles?
Syringes and needles are included in the ancillary kits provided by CDC to its jurisdictions. The US Government is overseeing ancillary kit distribution and coordination through McKesson and will provide syringes and needles to meet state, local, and tribal authority vaccination needs. This includes sourcing and providing as many low dead-volume syringes and needles as possible to facilitate extracting the labeled number of doses from the multiple dose vials. For further information, please reach out to your state, local, or tribal health department, or the CDC.9
Whom do I contact if my ancillary kit is damaged or lost?
Please contact McKesson Customer Service:
Phone #: 833-272-6634
Email: [email protected]
Whom do I contact if supplies in the ancillary kit are missing or damaged when opening the shipment?
Please contact McKesson Customer Service:
Phone #: 833-272-6634
Email: [email protected]
Whom do I contact for additional ancillary kit supplies (eg, vaccination cards, syringes, and/or needles)?
Please contact your Vaccine State Immunization Program Manager.

Diluent

OPEN ALL

CLOSE ALL

Which vaccine presentations require diluent?

The 6 months through 4 years of age, DILUTE BEFORE USE, Maroon Cap presentation, the 5 through 11 years of age, DILUTE BEFORE USE, Orange Cap presentation, and the 12 years of age and older, DILUTE BEFORE USE, Purple Cap presentation require diluent.3,5,6

For complete dose preparation and administration instructions, please refer to the Emergency Use Authorization (EUA) Fact Sheet for Vaccination Providers (6 months through 4 years of age), DILUTE BEFORE USE, Maroon Cap, the Emergency Use Authorization (EUA) Fact Sheet for Vaccination Providers (5 through 11 years of age), DILUTE BEFORE USE, Orange Cap, and the Emergency Use Authorization (EUA) Fact Sheet for Vaccination Providers (12 years of age and older), DILUTE BEFORE USE, Purple Cap.

The 12 years of age and older, DO NOT DILUTE, Gray Cap presentation does not require diluent and must NOT be diluted.4 For complete dose preparation and administration instructions, please refer to the Emergency Use Authorization (EUA) Fact Sheet for Vaccination Providers (12 years of age and older), DO NOT DILUTE, Gray Cap.
What type of diluent should I use with the 12 years of age and older, DILUTE BEFORE USE, Purple Cap presentation?

For the 12 years of age and older, DILUTE BEFORE USE, Purple Cap presentation dilute only with sterile 0.9% Sodium Chloride Injection, USP. DO NOT USE bacteriostatic saline.3

The 12 years of age and older, DO NOT DILUTE, Gray Cap presentation must NOT be diluted.4
How do I dilute the 12 years of age and older, DILUTE BEFORE USE, Purple Cap presentation for administration?
Dilute the thawed vial of vaccine by adding 1.8 mL of sterile 0.9% Sodium Chloride Injection, USP, into the vial. Do not add more than 1.8 mL of diluent.3 Please see the Emergency Use Authorization (EUA) Fact Sheet for Vaccination Providers (12 years of age and older), DILUTE BEFORE USE, Purple Cap and refer to the DOSAGE AND ADMINISTRATION section for specific guidelines on preparation of the vaccine.
Will the vaccine be supplied and shipped with the diluent?
The diluent will be packaged within the ancillary kits that may arrive 1 to 2 days before the vaccine shipment arrives.9
How can I order more diluent?
Diluent will be included in the ancillary kits provided by CDC to its jurisdictions. The US Government will oversee ancillary kit distribution and coordination, and will provide diluent to meet state, local, and tribal authority vaccination needs. If diluent has been damaged or lost, please call 1-800-666-7248.9
How many doses does each vial contain?
The 12 years of age and older, DILUTE BEFORE USE, Purple Cap presentation contains 6 doses of 0.3 mL of vaccine. Low dead-volume syringes and/or needles can be used to extract 6 doses from a single vial. If standard syringes and needles are used, there may not be sufficient volume to extract a sixth dose from a single vial. Irrespective of the type of syringe and needle3:
  • Each dose must contain 0.3 mL of vaccine
  • If the amount of vaccine remaining in the vial cannot provide a full dose of 0.3 mL, discard the vial and any excess volume
  • Do not pool excess vaccine from multiple vials

Please see the Emergency Use Authorization (EUA) Fact Sheet for Vaccination Providers (12 years of age and older), DILUTE BEFORE USE, Purple Cap and refer to the DOSAGE AND ADMINISTRATION section for instructions on preparation and administration.



The 12 years of age and older, DO NOT DILUTE, Gray Cap presentation contains 6 doses of 0.3 mL of vaccine. Low dead-volume syringes and/or needles can be used to extract 6 doses from a single vial. If standard syringes and needles are used, there may not be sufficient volume to extract a sixth dose from a single vial. Irrespective of the type of syringe and needle4:
  • Each dose must contain 0.3 mL of vaccine
  • If the amount of vaccine remaining in the vial cannot provide a full dose of 0.3 mL, discard the vial and any excess volume
  • Do not pool excess vaccine from multiple vials
Please see the Emergency Use Authorization (EUA) Fact Sheet for Vaccination Providers (12 years of age and older), DO NOT DILUTE, Gray Cap and refer to the DOSAGE AND ADMINISTRATION section for instructions on preparation and administration.
Can I use locally sourced diluent?
Yes, it is acceptable to use locally sourced sterile 0.9% Sodium Chloride Injection, USP. DO NOT use bacteriostatic saline.

Dosing and Administration

For complete dosage, preparation, and administration instructions for individuals 12 years of age and older, please refer to:
Full Prescribing Information (FDA Approved – 12 years of age and older), DO NOT DILUTE, Gray Cap
Full Prescribing Information (FDA Approved – 12 years of age and older), DILUTE BEFORE USE, Purple Cap
Emergency Use Authorization (EUA) Fact Sheet for Vaccination Providers (12 years of age and older), DO NOT DILUTE, Gray Cap
Emergency Use Authorization (EUA) Fact Sheet for Vaccination Providers (12 years of age and older), DILUTE BEFORE USE, Purple Cap

OPEN ALL

CLOSE ALL

How many doses are authorized for eligible immunocompromised individuals?

Immunocompromised individuals 5 years of age and older with certain kinds of immunocompromise are authorized under emergency use to receive a 3-dose primary series. The third primary series dose of the vaccine is administered at least 28 days following the second primary series dose.

After completion of the 3-dose primary series, immunocompromised individuals 12 years of age and older are also authorized to receive booster doses.3-5

Click here for complete dosing, preparation, and administration instructions for the 5 through 11 years of age, DILUTE BEFORE USE, Orange Cap presentation.
Certain kinds of immunocompromise refers to individuals who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.
How is the 12 years of age and older, DO NOT DILUTE, Gray Cap presentation different from the original 12 years of age and older, DILUTE BEFORE USE, Purple Cap presentation?

Each formulation has specific preparation and storage guidelines.3,4 Please see the Vaccine Formulation/Presentation Guide to review the differences in vaccine formulation/presentation.

For 12 years of age and older, DILUTE BEFORE USE, Purple Cap presentation DOSAGE AND ADMINISTRATION, please see the Emergency Use Authorization (EUA) Fact Sheet for Vaccination Providers (12 years of age and older), DILUTE BEFORE USE, Purple Cap

For 12 years of age and older, DO NOT DILUTE, Gray Cap presentation DOSAGE AND ADMINISTRATION, please see the Emergency Use Authorization (EUA) Fact Sheet for Vaccination Providers (12 years of age and older), DO NOT DILUTE, Gray Cap
Does the vaccine contain live virus?
No, the vaccine does not contain SARS-CoV-2 and cannot give one COVID-19.11
Do I need to wear gloves when handling individual vials?
Yes, when working with frozen individual vials, wear protective gloves in order to properly handle the vials.12
What are the ingredients included in the 12 years of age and older, DILUTE BEFORE USE, Purple Cap presentation?
Each 0.3 mL dose of the 12 years of age and older, DILUTE BEFORE USE, Purple Cap presentation contains 30 mcg of a nucleoside-modified messenger RNA (mRNA) encoding the viral spike (S) glycoprotein of SARS-CoV-2. Each 0.3 mL dose of the vaccine also includes the following ingredients: lipids (0.43 mg (4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 0.05 mg 2[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, 0.09 mg 1,2-distearoyl-sn-glycero-3-phosphocholine, and 0.2 mg cholesterol), 0.01 mg potassium chloride, 0.01 mg monobasic potassium phosphate, 0.36 mg sodium chloride, 0.07 mg dibasic sodium phosphate dihydrate, and 6 mg sucrose. The diluent (0.9% Sodium Chloride Injection, USP) contributes an additional 2.16 mg sodium chloride per dose.3
What are the ingredients included in the 12 years of age and older, DO NOT DILUTE, Gray Cap presentation?
Each 0.3 mL dose of the 12 years of age and older, DO NOT DILUTE, Gray Cap presentation contains 30 mcg of a nucleoside-modified messenger RNA (mRNA) encoding the viral spike (S) glycoprotein of SARS-CoV-2. Each 0.3 mL dose of the vaccine also includes the following ingredients: lipids (0.43 mg (4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 0.05 mg 2[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, 0.09 mg 1,2-distearoyl-sn-glycero-3-phosphocholine, and 0.19 mg cholesterol), 0.06 mg tromethamine, 0.4 mg tromethamine hydrochloride, and 31 mg sucrose.4
Can I give the vaccine at the same time as other vaccines?

According to the vaccine Fact Sheets, there is no information on the co-administration of this vaccine with other vaccines.3,4

Is the vaccine only available in a multiple dose vial?
Yes, the vaccine is only available in multiple dose vials.3,4
How do I prepare the dose?

Preparation of the dose is dependent on the cap color of the vaccine vial.

For Purple Cap vials, please see the Emergency Use Authorization (EUA) Fact Sheet for Vaccination Providers (12 years of age and older), DILUTE BEFORE USE, Purple Cap DOSAGE AND ADMINISTRATION section for instructions on how to prepare the vaccine.

For Gray Cap vials, please see the Emergency Use Authorization (EUA) Fact Sheet for Vaccination Providers (12 years of age and older), DO NOT DILUTE, Gray Cap DOSAGE AND ADMINISTRATION section for instructions on how to prepare the vaccine.
What syringes should I use for diluting?

A 3 mL syringe should be used for diluent withdrawal and mixing. A 5 mL syringe is also acceptable.12

Please see the Emergency Use Authorization (EUA) Fact Sheet for Vaccination Providers (12 years of age and older), DILUTE BEFORE USE, Purple Cap DOSAGE AND ADMINISTRATION section for instructions on vaccine preparation.
What syringes and needles should I use for administration?

Use a 1 mL syringe. Low dead-volume syringes and/or needles should be used. If standard syringes and needles are used, there may not be sufficient volume to extract the labeled number of doses from a single vial. If a low dead-volume syringe is not available, a standard 1 mL syringe may be used.12

What is the primary dosing schedule for the vaccine for individuals 12 years of age and older?

In individuals 12 years of age or older, the vaccine is administered as a 2-dose primary series (0.3 mL each) 3 weeks apart.3,4

A third dose of the vaccine (0.3 mL) administered at least 28 days following the first 2 doses of this vaccine is authorized for administration to individuals at least 12 years of age with certain kinds of immunocompromise.3,4

Certain kinds of immunocompromise refers to individuals who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.

For additional information, please refer to Select Information Related to Dosing Intervals for the Pfizer-BioNTech COVID-19 Vaccine.

Before administration of the vaccine, please click to see

Fact Sheets and Prescribing Information for individuals 12 years of age and older
Full Prescribing Information (12 years of age and older), DO NOT DILUTE, Gray Cap
Full Prescribing Information (12 years of age and older), DILUTE BEFORE USE, Purple Cap
Emergency Use Authorization (EUA) Fact Sheet for Vaccination Providers (12 years of age and older), DO NOT DILUTE, Gray Cap
Emergency Use Authorization (EUA) Fact Sheet for Vaccination Providers (12 years of age and older), DILUTE BEFORE USE, Purple Cap
Recipients and Caregivers Fact Sheet (12 years of age and older)
Are the FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and EUA-authorized Pfizer-BioNTech COVID-19 Vaccine interchangeable?
When prepared according to their respective instructions for use, the FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine for individuals 12 years of age and older can be used interchangeably without presenting any safety or effectiveness concerns. COMIRNATY® (COVID-19 Vaccine, mRNA) and the Pfizer-BioNTech COVID-19 Vaccine intended for individuals 12 years of age and older (purple cap and gray cap) should not be used for individuals 5 through 11 years of age because of the potential for vaccine administration errors, including dosing errors.
Are Pfizer-BioNTech COVID-19 Vaccine and COMIRNATY® interchangeable with other COVID-19 vaccines?

According to the CDC's Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States, in general, the same mRNA vaccine product (ie, the same manufacturer) should be used for all doses in the primary series, including an additional primary dose.13

Is the vaccine with the gray cap labeled “COMIRNATY” different than the vaccine with the gray cap labeled “Pfizer-BioNTech COVID-19 Vaccine”?
The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and the approved vaccine is marketed as COMIRNATY®, for the prevention of COVID-19 in individuals 12 years of age and older. The vaccine ingredients and formulation contained in all DO NOT DILUTE (Gray Cap) vaccine vials are the same. When prepared according to instructions for use, these can be used interchangeably for vaccinating people ages 12 and older. Gray cap vaccine should not be used to vaccinate people 5 through 11 years of age, or people 6 months through 4 years of age because of the potential for vaccine administration errors, including dosing errors.

Storage and Stability

OPEN ALL

CLOSE ALL

How are 12 years of age and older, DILUTE BEFORE USE, Purple Cap presentation vials stored?

Cartons of the 12 years of age and older, DILUTE BEFORE USE, Purple Cap presentation vials arrive in thermal shipping containers with dry ice. Once received, remove the vial cartons immediately from the thermal shipping container and preferably store in an ultra-low-temperature freezer between -90°C to -60°C (-130°F to -76°F) until the expiry date.3 Expiry date printed on vials and cartons may have been updated; see expiry table provided in the Fact Sheet and below.

If not stored between -90°C to -60°C (-130°F to -76°F), vials may be stored at -25°C to -15°C (-13°F to 5°F) for up to 2 weeks. Vials must be kept frozen and protected from light until ready to use. Vials stored at -25°C to -15°C (-13°F to 5°F) for up to 2 weeks may be returned 1 time to the recommended storage condition of -90°C to -60°C (-130°F to -76°F). Total cumulative time the vials are stored at -25°C to -15°C (-13°F to 5°F) should be tracked and should not exceed 2 weeks.

If an ultra-low-temperature freezer is not available, the thermal shipping container in which the vaccine vials arrive may be used as temporary storage when consistently re-filled to the top of the container with dry ice. Refer to the re-icing guidelines packed in the original thermal shipping container for instructions regarding the use of the thermal shipping container for temporary storage, or download here. The thermal shipping container maintains a temperature range of -90°C to -60°C (-130°F to -76°F). Storage of the vials between -96°C to -60°C (-141°F to -76°F) is not considered an excursion from the recommended storage condition.

If cartons or vials of 12 years of age and older, DILUTE BEFORE USE, Purple Cap presentation are received at 2°C to 8°C, they should be stored at 2°C to 8°C.12 Check that the carton has been updated to reflect the refrigerated expiry date.

Once vials are thawed they should not be refrozen.

faq-purple-image

Storage options for 12 years of age and older, DILUTE BEFORE USE,
Purple Cap presentation:

Storgae-purple-Dilution Storage-purple-Dilution

*Cartons and vials of Pfizer-BioNTech COVID-19 Vaccine with an expiry date of October 2021 through December 2022 (printed on label) may remain in use beyond the printed date until the updated expiry date shown below as long as approved storage conditions have been maintained.‡ Expiry information may be updated periodically, click here for updated expiry information.

Updated expiry dates are shown below.

Printed Expiry Date

12/2021

01/2022

02/2022

03/2022

06/2022

07/2022

08/2022

09/2022

10/2022

11/2022

12/2022

Updated Expiry Date

30-Jun-2022

31-Jul-2022

31-Aug-2022

30-Sep-2022

30-Sep-2022

31-Oct-2022

30-Nov-2022

31-Dec-2022

31-Jan-2023

28-Feb-2023

31-Mar-2023

†Refer to the dry ice replenishment guidelines packed in the original thermal shipping container for instructions regarding the use of the thermal shipping container for temporary storage or download here.

‡Regardless of storage condition, purple cap vaccine should not be used past the 12-month expiry. For vials with expiry dates of October 2021 through March 2022, the printed date on the label/carton reflects 6-month expiry. For vials with expiry dates of June 2022 through December 2022, the printed date on the label/carton reflects 9-month expiry. The vaccine should not be used past the 12-month (updated) expiry date in the table above.

If you have lots that will expire shortly, please see additional information about expiry dates.
Do I need to store the 12 years of age and older, DILUTE BEFORE USE, Purple Cap presentation vials in an ultra-low-temperature freezer?

Cartons of the 12 years of age and older, DILUTE BEFORE USE, Purple Cap presentation vials arrive in thermal shipping containers with dry ice. Once received, remove the vial cartons immediately from the thermal shipping container and preferably store in an ultra-low-temperature freezer between -90°C to -60°C (-130°F to -76°F) until the expiry date .3 Expiry date printed on vials and cartons may have been updated; see expiry table provided in the Fact Sheet and below.

If not stored between -90°C to -60°C (-130°F to -76°F), vials may be stored at -25°C to -15°C (-13°F to 5°F) for up to 2 weeks. Vials must be kept frozen and protected from light until ready to use. Vials stored at -25°C to -15°C (-13°F to 5°F) for up to 2 weeks may be returned 1 time to the recommended storage condition of -90°C to -60°C (-130°F to -76°F). Total cumulative time the vials are stored at -25°C to -15°C (-13°F to 5°F) should be tracked and should not exceed 2 weeks.

If an ultra-low-temperature freezer is not available, the thermal shipping container in which the vaccine vials arrive may be used as temporary storage when consistently re-filled to the top of the container with dry ice. Refer to the re-icing guidelines packed in the original thermal shipping container for instructions regarding the use of the thermal shipping container for temporary storage, or download here. The thermal shipping container maintains a temperature range of -90°C to -60°C (-130°F to -76°F). Storage of the vials between -96°C to -60°C (-141°F to -76°F) is not considered an excursion from the recommended storage condition.

If cartons or vials of 12 years of age and older, DILUTE BEFORE USE, Purple Cap presentation are received at 2°C to 8°C, they should be stored at 2°C to 8°C.12 Check that the carton has been updated to reflect the refrigerated expiry date.

Once vials are thawed they should not be refrozen.

faq-purple-image

Storage options for 12 years of age and older, DILUTE BEFORE USE,
Purple Cap presentation:

Storgae-purple-Dilution Storage-purple-Dilution

*Cartons and vials of Pfizer-BioNTech COVID-19 Vaccine with an expiry date of October 2021 through December 2022 (printed on label) may remain in use beyond the printed date until the updated expiry date shown below as long as approved storage conditions have been maintained.‡ Expiry information may be updated periodically, click here for updated expiry information.

Updated expiry dates are shown below.

Printed Expiry Date

12/2021

01/2022

02/2022

03/2022

06/2022

07/2022

08/2022

09/2022

10/2022

11/2022

12/2022

Updated Expiry Date

30-Jun-2022

31-Jul-2022

31-Aug-2022

30-Sep-2022

30-Sep-2022

31-Oct-2022

30-Nov-2022

31-Dec-2022

31-Jan-2023

28-Feb-2023

31-Mar-2023

†Refer to the dry ice replenishment guidelines packed in the original thermal shipping container for instructions regarding the use of the thermal shipping container for temporary storage or download here.

‡Regardless of storage condition, purple cap vaccine should not be used past the 12-month expiry. For vials with expiry dates of October 2021 through March 2022, the printed date on the label/carton reflects 6-month expiry. For vials with expiry dates of June 2022 through December 2022, the printed date on the label/carton reflects 9-month expiry. The vaccine should not be used past the 12-month (updated) expiry date in the table above.

If you have lots that will expire shortly, please see additional information about expiry dates.
How are 12 years of age and older, DO NOT DILUTE, Gray Cap presentation vials stored?

The 12 years of age and older, DO NOT DILUTE, Gray Cap presentation vials may arrive frozen at ultra-cold conditions in thermal shipping containers with dry ice. DO NOT DILUTE formulation vials may be immediately transferred to the refrigerator at 2°C to 8°C (35°F to 46°F), thawed and stored for up to 10 weeks. The 10-week refrigerated expiry date should be recorded on the carton at the time of transfer.4

Alternatively, 12 years of age and older, DO NOT DILUTE, Gray Cap presentation vials received at ultra-cold temperatures may be stored in an ultra-low-temperature freezer at -90°C to -60°C (-130°F to -76°F) for up to 12 months from the date of manufacture. Once vials are thawed, they should not be refrozen.

If cartons or vials of 12 years of age and older, DO NOT DILUTE, Gray Cap presentation are received at 2°C to 8°C, they should be stored at 2°C to 8°C. Check that the carton has been updated to reflect the refrigerated expiry date.

faq-gray-image

Storage options for 12 years of age and older, DILUTE BEFORE USE,
Gray Cap presentation:

Storgae-gray-Dilution Storgae-gray-Dilution

Regardless of storage condition, gray cap vaccine should not be used after 12 months from the date of manufacture printed on the vial and cartons. Expiry dates based on 12 months from the date of manufacture are shown below.4

Pfizer-BioNTech COVID-19 Vaccine - labeled vials

Printed Manufacturing Date

07/2021

08/2021

09/2021

10/2021

11/2021

12/2021

01/2022

02/2022

12-Month Expiry Date

30-Jun-2022

31-Jul-2022

31-Aug-2022

30-Sep-2022

31-Oct-2022

30-Nov-2022

31-Dec-2022

31-Jan-2023

COMIRNATY® (COVID-19 Vaccine, mRNA) - labeled vials

Printed Expiry Date

09/2022

10/2022

Updated Expiry Date

31-Dec-2022

31-Jan-2023

If you have lots that will expire shortly, please see additional information about expiry dates.
Do I need to store the 12 years of age and older, DO NOT DILUTE, Gray Cap presentation vials in an ultra-low-temperature freezer?

The 12 years of age and older, DO NOT DILUTE, Gray Cap presentation vials may be immediately transferred to the refrigerator [2°C to 8°C (35°F to 46°F)], thawed and stored for up to 10 weeks. The 10-week refrigerated expiry date should be recorded on the carton at the time of transfer. A carton of 10 vials may take up to 6 hours to thaw at this temperature.4

Alternatively, frozen vials may be stored in an ultra-low-temperature freezer at -90°C to -60°C (-130°F to -76°F) for up to 12 months from the date of manufacture. Do not store vials at -25°C to -15°C (-13°F to 5°F). Once vials are thawed, they should not be refrozen.

If cartons or vials of 12 years of age and older, DO NOT DILUTE, Gray Cap presentation are received at 2°C to 8°C, they should be stored at 2°C to 8°C. Check that the carton has been updated to reflect the 10-week refrigerated expiry date.

Storgae-gray-Dilution Storgae-gray-Dilution

Regardless of storage condition, gray cap vaccine should not be used after 12 months from the date of manufacture printed on the vial and cartons. Expiry dates based on 12 months from the date of manufacture are shown below.4

Pfizer-BioNTech COVID-19 Vaccine - labeled vials

Printed Manufacturing Date

07/2021

08/2021

09/2021

10/2021

11/2021

12/2021

01/2022

02/2022

12-Month Expiry Date

30-Jun-2022

31-Jul-2022

31-Aug-2022

30-Sep-2022

31-Oct-2022

30-Nov-2022

31-Dec-2022

31-Jan-2023

COMIRNATY® (COVID-19 Vaccine, mRNA) - labeled vials

Printed Expiry Date

09/2022

10/2022

Updated Expiry Date

31-Dec-2022

31-Jan-2023

If you have lots that will expire shortly, please see additional information about expiry dates.
How do I know if the thermal shipping container I received with my vaccine shipment can be used as temporary cold storage?

The vaccine supply you received was shipped in 1 of 2 types of containers: a Medium (Reusable) Thermal Shipping Container or a Single-Use Thermal Shipping Container.

The type of thermal shipping container you received is labeled on the outside of the box as either “Medium ULT” (or otherwise indicates “Do Not Discard”), or “Single-Use ULT.” Look for this label in order to determine the type of container you have received. Only the Medium ULT may be used as temporary storage of the vaccine for up to 30 days. If you are using the Medium ULT as temporary storage, the container must be opened, inspected, and replenished with dry ice within 24 hours of receipt.12 Refer to the Dry Ice Replenishment Instructions packed in the thermal shipping container (or download here) for instructions regarding the use of the thermal shipping container for temporary storage of your vaccine supply.

The Single-Use ULT cannot be used as temporary storage due to its design. Upon delivery of this type of container, follow instructions for proper disposal of the Single-Use ULT shipping container, available from cvdvaccine-us.com.
How do I know when my vials expire?
Please click here for expiry information.
Do the formulations of DILUTE BEFORE USE and DO NOT DILUTE vials impact the efficacy and safety of the vaccine?
No, the differences in presentation do not impact the active ingredient, and the formulations are considered equivalent for safety and efficacy.3,4
Can I still use the product if it has become frozen after it is originally thawed?
No, you should not use the vaccine if it has become frozen after thawing. The vaccine must then be discarded in a sharps container.14 If you are a healthcare professional in the US and want additional information, visit https://www.pfizermedicalinformation.com/en-us/pfizer-biontech-covid-19-vaccine or call 1-800-438-1985 to talk to a Pfizer Medical Information representative.
How long can I store the vaccine in the Medium Thermal Shipping Container?

With proper dry ice replenishment, the Medium Thermal Shipping Container may be used as temporary storage for up to 30 days from delivery.12 Please see Shipping and Handling Guidelines for the Medium Thermal Shipping Container for more information.

The Single-Use Thermal Shipping container cannot be used as temporary storage.

After use, the Medium Thermal Shipping Container, including the Temperature-Monitoring Device, must be returned to the supplier to help Pfizer fulfill its commitment to reusable resources. Please refer to the Return Instructions available on cvdvaccine-us.com for more information.
Where can I get an ultra-low-temperature freezer?

Ultra-low-temperature freezer vendors* include but are not limited to Thermo Fisher Scientific, Haier Biomedical, and Stirling Ultracold.

*This information is based on the data provided by the vendors listed. By including them, Pfizer is not endorsing the vendors nor making guarantees about their products. Please contact the vendor directly for availability. If you are a vendor and would like to add, edit, or delete your information, please call 1-877-829-2619 .
Is there preservative in the vaccine?
No, the vaccine does not contain preservative.3,4
Can I still use the product if it has been exposed to light?

During storage, minimize exposure to room light, and avoid exposure to direct sunlight and ultraviolet light. Thawed vials can be handled in room light conditions.3,4

If you are a healthcare professional residing in the US and have questions about using the vaccine, call 1-800-438-1985 to talk to a Pfizer Medical Information Specialist or go to https://www.pfizermedicalinformation.com/en-us/pfizer-biontech-covid-19-vaccine for more information.
How long does it take for frozen 12 years of age and older, DILUTE BEFORE USE, Purple Cap presentation vials to thaw?
In the refrigerator at 2°C to 8°C (35°F to 46°F)3:
  • 25-pack cartons may take up to 2 hours to thaw

  • 195-pack cartons may take up to 3 hours to thaw
Individual vials will take less time. If needed, a frozen vial may be thawed at room temperature (up to 25°C [77°F]) for 30 minutes.
How long does it take for frozen 12 years of age and older, DO NOT DILUTE, Gray Cap presentation vials to thaw?
In the refrigerator at 2°C to 8°C (35°F to 46°F)4:
  • 10-pack cartons may take up to 6 hours to thaw
Individual vials will take less time. If needed, a frozen vial may be thawed at room temperature (up to 25°C [77°F]) for 30 minutes.
Are components of the vaccine vial made with latex?
The vial stoppers are not made with natural rubber latex.3,4

Dry Ice

Only Medium Thermal Shipping Containers can be replenished with dry ice and used for temporary storage.12

The Single-Use Thermal Shipping Container cannot be used as temporary storage.

OPEN ALL

CLOSE ALL

Do I still need to monitor the temperature if I am using dry ice?
Yes, the temperature of vaccine product must always be monitored in accordance with local requirements.12 Please refer to the CDC’s Vaccine Storage and Handling Toolkit for guidance on storage and handling of vaccines at www.cdc.gov/vaccines/hcp/admin/storage/toolkit/index.html.
How often do I need to add dry ice to the thermal shipping container?

If you are using the Medium Thermal Shipping Container as temporary storage, the container must be opened, inspected, and replenished with dry ice within 24 hours of receipt. Do not open the vial cartons or remove vials until you are ready for thawing or use. It is recommended that the thermal shipping container not be opened more than 2 times a day and should not be opened for more than 3 minutes at a time. If these guidelines are followed, the thermal shipping container should be replenished with dry ice every 5 days. If the thermal shipping container is opened more frequently, replenishment will need to occur more often.12 Please refer to the Storage & Handling section for instructions for replenishing dry ice.

The Single-Use Thermal Shipping Container cannot be used as temporary storage.
How do I refill the Medium Thermal Shipping Container with dry ice?

Fill any low areas in the side compartments of the thermal shipping container with dry ice pellets until completely filled, so that it is equal with but does not exceed the top edges of the box that holds the vial cartons. Reinsert the dry ice pod on top of the box that holds the vial cartons. Then fill the dry ice pod to the top with dry ice (do not overfill).12

For more information, please see the Dry Ice Replenishment Instructions for Medium (Reusable) Thermal Shipping Containers.
Where and how can I get more dry ice?

Dry ice vendors* include but are not limited to Airgas, Linde, Continental Carbonic Products Inc, and Matheson.12

*This information is based on the data provided by the vendors listed. By including them, Pfizer is not endorsing the vendors nor making guarantees about their products. Please contact the vendor directly for availability. If you are a vendor and would like to add, edit, or delete your information, please call 1-877-829-2619.
Is there a limit to how long I can use dry ice to maintain temperature, and how many times can I refill the container with dry ice?

The Medium Thermal Shipping Container may be used as temporary storage for up to 30 days from delivery. It is recommended that the thermal shipping container not be opened more than 2 times a day, and shouldn’t be opened for more than 3 minutes at a time. If these guidelines are followed, after dry ice replenishment within 24 hours, the thermal shipping container should then be replenished with dry ice every 5 days. If the thermal shipping container is opened more frequently, replenishment will need to occur more often.12

The Single-Use Thermal Shipping Container cannot be used as temporary storage.

For more information, please see the Dry Ice Replenishment Instructions for Medium (Reusable) Thermal Shipping Containers.
What type of protective gear should be worn when handling dry ice?
Wear safety goggles or safety glasses with side shields and waterproof insulated gloves for handling dry ice.12 Click here to view the Dry Ice Safety Data Sheet.
How do I dispose of dry ice when I no longer need it?
Dry ice can be hazardous. Take necessary precautions by reviewing the Dry Ice Safety Data Sheet in the Resources and consulting with your Occupational Health Department. To discard the dry ice, open the thermal shipping container and leave it at room temperature in a well-ventilated area. The dry ice will sublime from a solid to a gas.12
What type of gloves should I use when transferring vial cartons from the thermal shipping container?
Wear waterproof insulated gloves to prevent skin contact while transferring vial cartons from the thermal shipping container.12

Thermal Shipping Container

OPEN ALL

CLOSE ALL

How do I follow up on the status of my product order?
If you are a healthcare professional trying to locate your order of the vaccine and you reside in the US, you can call 1-800-666-7248.
Whom do I contact if I have an issue with my shipment?
If you are a healthcare professional having an issue with your shipment of the vaccine and you reside in the US, you can call 1-800-666-7248.
What type of gloves should I use when transferring vial cartons from the thermal shipping container?
Wear waterproof insulated gloves to prevent skin contact while transferring vial cartons from the thermal shipping container.13
How can I return the Medium Thermal Shipping Container and Temperature-Monitoring Device?

To return the Medium Thermal Shipping Container and Temperature-Monitoring Device, use the preprinted return shipping label included inside the container and apply over the existing shipping label. Some thermal shipping containers have the preprinted return shipping label already adhered to the flap of the thermal shipping container. After the thermal shipping container is no longer needed to store the vaccine, you should discard the dry ice. To discard, open the thermal shipping container and leave it at room temperature in a well-ventilated area. The dry ice will sublime from a solid to a gas. Take necessary precautions by reviewing the Dry Ice Safety Data Sheet and consulting with your Occupational Health Department.12

Ensure the Dry Ice UN1845 markings and diamond-shaped Class 9 hazard label on the thermal shipping container are covered by placing a blank label over them in preparation for the return, as the container no longer contains dry ice. Blank sticker labels to place over the UN1845 markings can be found on the back page of the Shipping and Handling Guidelines included in the thermal shipping container. A label may also be found on the inside flap of some thermal shipping containers. You can contact the carrier identified on the return label to arrange the return.12

Please refer to the Return Instructions for complete information.

For additional assistance on returns, call 1-701-540-4039 if in the US.
How can I return the Temperature-Monitoring Device included with the Single-Use Thermal Shipping Container?

Remove the Temperature-Monitoring Device Return Kit from the flap of the Single-Use Thermal Shipping Container. Then, gently remove the Temperature-Monitoring Device with the probe from the foam lid (or foam compartment on box flap) and payload area.12

For complete instructions on how to return the Temperature-Monitoring Device using the included Temperature-Monitoring Device Return Kit, please refer to the Return Instructions. Do not return the vaccine or vaccine vials.

After removal of the Temperature-Monitoring Device and Temperature-Monitoring Device Return Kit, the Single-Use Thermal Shipping Container should be disposed of at your facility.

For complete instructions on how to dispose of the Single-Use Thermal Shipping Container, please refer to the Return Instructions.
How should I handle the dry ice inside the thermal shipping container?
Dry ice can be hazardous. Take necessary precautions by reviewing the Dry Ice Safety Data Sheet, and consulting with your Occupational Health Department. Ensure there is proper ventilation and wear safety goggles or safety glasses with side shields and waterproof insulated gloves when working with dry ice.12 Please visit the Storage & Handling section for step-by-step instructions for safely handling the thermal shipping container.
The Controlant Real-Time Monitor status light is red. What should I do?

When the shipment status light is red, this means that the device is functioning properly but has recorded an out-of-range temperature.12

You will automatically receive a shipment delivery email from Controlant, the temperature-monitoring device company. This email will include a Quality Disposition Report, which will confirm the product disposition and actions required if the status light is red.12

Do not use product until you have received the Quality Disposition Report from Controlant advising on further use.
Can I use the Controlant Real-Time Monitor to monitor the vaccine temperature while using the thermal shipping container as my storage unit?
Yes, you will be able to use the temperature-monitoring device to monitor the vaccine temperature.12 Contact Controlant customer service at: 1-701-540-4039 or visit https://in.controlant.com/onsitemonitoring to access the Controlant Onsite Monitoring Playbook and instructional videos.
What are the weights and dimensions of the thermal shipping container and vial cartons?
  • External Dimensions of the AeroSafe 47L7: 17.5" x 17.5" x 21.5"
  • External Dimensions of Softbox Medium ULT: 15.75" x 15.75" x 22.05"
  • Dimension of one 10-pack carton: from approximately 3.35" x 1.46" x 1.85" to 3.50" x 1.46" x 1.85"
  • Dimension of one 25-pack carton: 3.31" x 3.35" x 1.54"
  • Dimension of one 195-pack carton*: 9.09" x 9.09" x 1.65"
  • Weight range for the Medium ULT thermal shipping containers: approximately 64 lb to 80 lb (29 kg to 36 kg)
  • External Dimensions of the Sonoco Single Use Thermal Shipper: ~17.32" x 16.18" x 18.94"
  • External Dimensions of the CCT Single Use Thermal Shipper: ~19.76" x 15.75" x 15.51"
    • *Please note that dimensions can vary depending on the shipping mode or manufacturing site.

Ensuring Authenticity

OPEN ALL

CLOSE ALL

How can I verify if the vaccine product I receive is authentic?
Ensuring the Authenticity of Pfizer-BioNTech COVID-19 Vaccine and Registered Trademark Name COMIRNATY®
  • Pfizer is committed to patient safety and ensuring that people have accurate information about the vaccine, including how it is accessed and administered. We are actively monitoring for fraudulent offers of illegitimate vaccines to protect patients from products that might be dangerous and lead to serious and life-threatening harm
    • The vaccine is only administered intramuscularly by a healthcare professional1,2
    • The vaccine is not taken orally and is not available in a capsule or tablet form1,2
  • Authentic vaccines, manufactured by Pfizer Inc, will include the Pfizer and BioNTech names on the label and are dispensed in a vial as follows:
    • For 6 months through 4 years of age, DILUTE BEFORE USE, Maroon Cap presentation, the vial label includes a maroon border6
    • For 5 through 11 years of age, DILUTE BEFORE USE, Orange Cap presentation, the vial label includes an orange border5
    • For 12 years of age and older, DO NOT DILUTE, Gray Cap presentation, the vial label includes a gray border4
    • For 12 years of age and older, DILUTE BEFORE USE, Purple Cap presentation, two versions of the vial label are in current circulation—with or without a purple border3

  • Ensure the safety of the vaccine vials by limiting access to only authorized personnel. The location they are stored in must be secure and locked when not in use. To prevent counterfeits, discard vaccine vials in sharps containers and empty vial cartons as medical waste or deface or safely crush all materials so they cannot be reused. Remember, the vaccines are only available through government-authorized vaccination centers – such as doctor’s offices, authorized pharmacies, outpatient clinics, community vaccination locations, and hospitals. The vaccine can only be administered by licensed healthcare professionals, or other individuals that are approved vaccinators, at government-authorized vaccination sites. Individual doses are not for sale9,13

If you suspect the vaccine you have purchased may be counterfeit, contact us at 1-800-438-1985 or visit https://www.pfizer.com/products/product-contact-information.

What do the cartons and vials look like?

195-pack cartons:

25-pack cartons:

10-pack cartons:




The 12 years of age and older, DILUTE BEFORE USE, Purple Cap presentation vaccine is contained in 2 mL type 1 glass preservative-free multiple dose vials with 0.45 mL of frozen liquid drug product3,12:

12 years of age and older, DILUTE BEFORE USE, Purple Cap presentation vial:

The 12 years of age and older, DO NOT DILUTE, Gray Cap presentation vaccine is contained in 2 mL type 1 glass preservative-free multiple dose vials with 2.25 mL of frozen liquid drug product4,12:

12 years of age and older, DO NOT DILUTE, Gray Cap presentation vial:

What is the NDC?

The NDC for COMIRNATY® Suspension for Intramuscular Injection multiple dose vials with purple caps and labels with purple borders, supplied in a carton containing 25 multiple dose vials is 0069-1000-03. The NDC for the carton containing 195 multiple dose vials is 0069-1000-02.

The NDC for Pfizer-BioNTech COVID-19 Vaccine vials with a purple cap supplied in a carton containing 25 multiple dose vials is 59267-1000-3. The NDC for the carton containing 195 multiple dose vials is 59267-1000-2.

The NDC for COMIRNATY® Suspension for Intramuscular Injection multiple dose vials with gray caps and labels with gray borders, supplied in a carton containing 10 multiple dose vials is 0069-2025-10. The NDC for the carton containing 25 multiple dose vials is 0069-2025-25.

The NDC for Pfizer-BioNTech COVID-19 Vaccine vials with a gray cap supplied in a carton containing 10 multiple dose vials is 59267-1025-4. The NDC for the carton containing 25 multiple dose vials is 59267-1025-3.

Related pages:

Storage & Handling Dosing & Preparation Resources

Ensuring the Authenticity of Pfizer-BioNTech COVID-19 Vaccine and Registered Trademark Name COMIRNATY®

  • Pfizer is committed to patient safety and ensuring that people have accurate information about the vaccine, including how it is accessed and administered. We are actively monitoring for fraudulent offers of illegitimate vaccines to protect patients from products that might be dangerous and lead to serious and life-threatening harm
    • The vaccine is only administered intramuscularly by a healthcare professional1,2
    • The vaccine is not taken orally and is not available in a capsule or tablet form1,2
  • Authentic vaccines, manufactured by Pfizer Inc., will include the Pfizer and BioNTech names on the label and are dispensed in a vial as follows:
    • For 6 months through 4 years of age, DILUTE BEFORE USE, Maroon Cap vials, the vial label includes a maroon border646
    • For 5 through 11 years of age, DILUTE BEFORE USE, Orange Cap vials, the vial label includes an orange border55
    • For 12 years of age and older, DO NOT DILUTE, Gray Cap vials, the vial label includes a gray border44
    • For 12 years of age and older, DILUTE BEFORE USE, Purple Cap vials. Two versions of the vial label are in current circulation - with or without a purple border33
  • Ensure the safety of the vaccine vials by limiting access to only authorized personnel. The location they are stored in must be secure and locked when not in use.
    To prevent counterfeits, discard vaccine vials in sharps containers and empty vial cartons as medical waste or deface or safely crush all materials so they cannot be reused. Remember, the vaccines are only available through government-authorized vaccination centers – such as doctor’s offices, authorized pharmacies, outpatient clinics, community vaccination locations, and hospitals. The vaccine can only be administered by licensed healthcare professionals, or other individuals that are approved vaccinators, at government-authorized vaccination sites. Individual doses are not for sale6,78,128,128,99,13

If you suspect the vaccine you have purchased may be counterfeit, contact us at 1-800-438-1985 or visit https://www.pfizer.com/products/product-contact-information.

To learn more, visit https://www.pfizer.com/counterfeiting/frequently-asked-questions.

References
  1. COMIRNATY® (COVID-19 Vaccine, mRNA). Prescribing Information (12 years of age and older), DILUTE BEFORE USE, Purple Cap. Pfizer and BioNTech; July 8, 2021.
  2. COMIRNATY® (COVID-19 Vaccine, mRNA). Prescribing Information (12 years of age and older), DO NOT DILUTE, Gray Cap. Pfizer and BioNTech; July 8, 2021.
  3. Pfizer-BioNTech COVID-19 Vaccine. Emergency Use Authorization Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) (12 years of age and older), DILUTE BEFORE USE, Purple Cap. Pfizer and BioNTech; July 8, 2022.
  4. Pfizer-BioNTech COVID-19 Vaccine. Emergency Use Authorization Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) (12 years of age and older), DO NOT DILUTE, Gray Cap. Pfizer and BioNTech; July 8, 2022.
  5. Pfizer-BioNTech COVID-19 Vaccine. Emergency Use Authorization Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) (5 through 11 years of age), DILUTE BEFORE USE, Orange Cap. Pfizer and BioNTech; June 17, 2022.
  6. Pfizer-BioNTech COVID-19 Vaccine. Emergency Use Authorization Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) (6 months through 4 years of age), DILUTE BEFORE USE, Maroon Cap. Pfizer and BioNTech; June 17, 2022.
  7. Understanding the regulatory terminology of potential preventions and treatments for COVID-19. US Food & Drug Administration. Accessed December 10, 2021. https://www.fda.gov/consumers/consumer-updates/understanding- regulatory-terminology-potential-preventions-and-treatments-covid-19
  8. Proprietary name review for biologic products. US Food & Drug Administration. Accessed December 10, 2021. https://www.fda.gov/vaccines-blood-biologics/labeling-cber-regulatedproducts/proprietary-name-review-biologic- products
  9. COVID-19 Vaccination Program Interim Playbook for Jurisdiction Operations – September 16, 2020 Version 1.0. Centers for Disease Control and Prevention; 2020.
  10. Biden administration purchases additional doses of COVID-19 vaccines from Pfizer and Moderna. US Department of Health & Human Services. Accessed August 16, 2021. https://www.hhs.gov/about/news/2021/02/11/biden- administration-purchases-additional-doses-covid-19-vaccines-from-pfizer-and-moderna.html
  11. Myths and facts about COVID-19 vaccines. Centers for Disease Control and Prevention. Accessed August 11, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/facts.html
  12. Data on file. Pfizer Inc. New York, NY.
  13. Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. Centers for Disease Control and Prevention. Accessed March 2, 2022. https://www.cdc.gov/vaccines/covid-19/ clinical-considerations/covid-19-vaccines-us.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2F vaccines%2Fcovid-19%2Finfo-by-product%2Fclinical-considerations.html%5D.
  14. McCurry MC. Secure disposal of vaccine vials and packaging recommendations. US Department of Defense; 2020.

Indication & Authorized Use

Indication & Authorized Use

Important Safety Information

MORE

Important Safety Information

MORE


Indication & Authorized Use


COMIRNATY® (COVID-19 Vaccine, mRNA) is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older. It is also authorized for emergency use to provide a third primary series dose to individuals 12 years of age and older with certain kinds of immunocompromise.

Pfizer-BioNTech COVID-19 Vaccine

Authorized Use

Pfizer-BioNTech COVID-19 Vaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 6 months of age and older.

Interchangeability (Primary Series for Individuals 12 Years of Age and Older)

When prepared according to their respective instructions for use, the FDA-approved COMIRNATY and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine for individuals 12 years of age and older can be used interchangeably without presenting any safety or effectiveness concerns.

Because of the potential for vaccine administration errors, including dosing errors, vaccine presentations should only be used for the ages specified on the vial labels, cartons, or the respective age-based Fact Sheet. The information in the Fact Sheets supersedes the information printed on the vial labels and cartons.

Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)

Authorized Use

Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), hereafter referred to as Pfizer-BioNTech COVID-19 Vaccine, Bivalent is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older.


Important Safety Information

Do not administer Pfizer-BioNTech COVID-19 Vaccine, COMIRNATY, or Pfizer-BioNTech COVID-19 Vaccine, Bivalent to individuals with known history of a severe allergic reaction (eg, anaphylaxis) to any component of these vaccines.

Management of Acute Allergic Reactions

Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer-BioNTech COVID-19 Vaccine, COMIRNATY, or the Pfizer-BioNTech COVID-19 Vaccine, Bivalent.

Monitor vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html).

Myocarditis and Pericarditis

Myocarditis and pericarditis have been reported following administration of the Pfizer-BioNTech COVID-19 Vaccine.

Postmarketing safety data with Pfizer-BioNTech COVID-19 Vaccine are relevant to Pfizer-BioNTech COVID-19 Vaccine, Bivalent because these vaccines are manufactured using the same process.

Postmarketing data with authorized or approved monovalent mRNA COVID-19 vaccines demonstrate increased risks of myocarditis and pericarditis, particularly within the first week following receipt of the second primary series dose or first booster dose, with most booster doses likely administered at least 5 months after completing primary vaccination. For the Pfizer-BioNTech COVID-19 Vaccine, the observed risk is higher among adolescent males and adult males under 40 years of age than among females and older males, and the observed risk is highest in males 12 through 17 years of age. Although some cases required intensive care support, available data from short-term follow-up suggest that most individuals have had resolution of symptoms with conservative management. Information is not yet available about potential long-term sequelae. The CDC has published considerations related to myocarditis and pericarditis after vaccination, including for vaccination of individuals with a history of myocarditis or pericarditis (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html).

Syncope

Syncope (fainting) may occur in association with administration of injectable vaccines, in particular in adolescents. Procedures should be in place to avoid injury from fainting.

Altered Immunocompetence

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to Pfizer-BioNTech COVID-19 Vaccine, COMIRNATY or the Pfizer-BioNTech COVID-19 Vaccine, Bivalent.

Limitation of Effectiveness

Pfizer-BioNTech COVID-19 Vaccine, COMIRNATY or the Pfizer-BioNTech COVID-19 Vaccine, Bivalent may not protect all vaccine recipients.

Adverse Reactions

Primary Series Adverse Events:

Pfizer-BioNTech COVID-19 Vaccine

In a clinical study (3 mcg modRNA) in participants 6 through 23 months of age, adverse reactions following administration of any dose included irritability (68.4%), decreased appetite (38.6%), tenderness at the injection site (26.4%), injection site redness (17.8%), fever (14.4%), injection site swelling (7.3%), and lymphadenopathy (0.2%).

In a clinical study (3 mcg modRNA) in participants 2 through 4 years of age, adverse reactions following administration of any dose included pain at the injection site (47.0%), fatigue (44.8%), injection site redness (18.9%), fever (10.5%), headache (8.7%), injection site swelling (8.4%), chills (5.7%), muscle pain (5.0%), joint pain (2.4%), and lymphadenopathy (0.1%).

In a clinical study (10 mcg modRNA) in children 5 through 11 years of age, adverse reactions following administration of any primary series dose included pain at the injection site (84.3%), fatigue (51.7%), headache (38.2%), injection site redness (26.4%), injection site swelling (20.4%), muscle pain (17.5%), chills (12.4%), fever (8.3%), joint pain (7.6%), lymphadenopathy (0.9%), nausea (0.4%), rash (0.3%), malaise (0.1%), and decreased appetite (0.1%).

Pfizer-BioNTech COVID-19 Vaccine and COMIRNATY

In clinical studies (30 mcg modRNA) of adolescents 12 through 15 years of age, the most commonly reported adverse reactions (≥8%) were pain at the injection site (90.5%), fatigue (77.5%), headache (75.5%), chills (49.2%), muscle pain (42.2%), fever (24.3%), joint pain (20.2%), injection site swelling (9.2%), and injection site redness (8.6%).

In clinical studies (30 mcg modRNA) of participants 16 through 55 years of age, the most commonly reported adverse reactions (≥10%) were pain at the injection site (88.6%), fatigue (70.1%), headache (64.9%), muscle pain (45.5%), chills (41.5%), joint pain (27.5%), fever (17.8%), and injection site swelling (10.6%).

In clinical studies (30 mcg modRNA) of participants 56 years of age and older, the most commonly reported adverse reactions (≥10%) were pain at the injection site (78.2%), fatigue (56.9%), headache (45.9%), muscle pain (32.5%), chills (24.8%), joint pain (21.5%), injection site swelling (11.8%), fever (11.5%), and injection site redness (10.4%).

Booster Dose Adverse Events:

Pfizer-BioNTech COVID-19 Vaccine

In a clinical study (10 mcg modRNA) in children 5 through 11 years of age, adverse reactions following administration of a single booster dose were injection site pain (73.9%), fatigue (45.6%), headache (34.0%), muscle pain (18.3%), injection site swelling (16.4%), injection site redness (15.6%), chills (10.5%), fever (6.7%), joint pain (6.7%), diarrhea (4.9%), lymphadenopathy (2.5%), and vomiting (2.4%).

Pfizer-BioNTech COVID-19 Vaccine and COMIRNATY

In a clinical study (30 mcg modRNA) of participants 18 through 55 years of age, adverse reactions following administration of a first booster dose were pain at the injection site (83.0%), fatigue (63.7%), headache (48.4%), muscle pain (39.1%), chills (29.1%), joint pain (25.3%), lymphadenopathy (5.2%), nausea (0.7%), decreased appetite (0.3%), rash (0.3%), and pain in extremity (0.3%).

Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)

The safety of a booster dose of Pfizer-BioNTech COVID-19 Vaccine, Bivalent is based on:

  • safety data from a clinical study which evaluated a booster dose of Pfizer-BioNTech’s bivalent COVID-19 vaccine (Original and Omicron BA.1), not authorized or approved, hereafter referred to as bivalent vaccine (Original and Omicron BA.1),
  • safety data from clinical trials which evaluated primary and booster vaccination with Pfizer-BioNTech COVID-19 Vaccine, and
  • post marketing safety data with Pfizer-BioNTech COVID-19 Vaccine.

The safety data accrued with the bivalent vaccine (Original and Omicron BA.1) and with Pfizer-BioNTech COVID-19 Vaccine are relevant to Pfizer-BioNTech COVID-19 Vaccine, Bivalent because these vaccines are manufactured using the same process.

The clinical study that evaluated a booster dose of the bivalent vaccine (Original and Omicron BA.1) included participants 55 years of age and older. Adverse reactions following administration of the bivalent vaccine (Original and Omicron BA.1) as a second booster dose included pain at the injection site (58.1%), fatigue (49.2%), headache (33.6%), muscle pain (22.3%), chills (13.0%), joint pain (11.3%), injection site redness (7.0%), injection site swelling (6.6%), fever (5.0%), lymphadenopathy (0.3%), nausea (0.3%), and malaise (0.3%).

In a clinical study of participants 18 through 55 years of age, adverse reactions following administration of a first booster dose of Pfizer-BioNTech COVID-19 Vaccine were pain at the injection site (83.0%), fatigue (63.7%), headache (48.4%), muscle pain (39.1%), chills (29.1%), joint pain (25.3%), lymphadenopathy (5.2%), nausea (0.7%), decreased appetite (0.3%), rash (0.3%), and pain in extremity (0.3%).

Post Authorization Experience

Severe allergic reactions, including anaphylaxis, and other hypersensitivity reactions (eg, rash, pruritus, urticaria, angioedema), diarrhea, vomiting, pain in extremity (arm), and syncope have been reported following administration of the Pfizer-BioNTech COVID-19 Vaccine.

Myocarditis and pericarditis have been reported following administration of the Pfizer-BioNTech COVID-19 Vaccine.

Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of Pfizer-BioNTech COVID-19 Vaccine and post authorization use of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent.

Before administration of Pfizer-BioNTech COVID-19 Vaccine, please click to see

Fact Sheets for individuals 6 months through 4 years of age
EUA Fact Sheet for Vaccination Providers (6 months through 4 years of age),
DILUTE BEFORE USE, Maroon Cap
Recipients and Caregivers Fact Sheet (6 months through 4 years of age)
Fact Sheets for individuals 5 through 11 years of age
EUA Fact Sheet for Vaccination Providers (5 through 11 years of age), DILUTE BEFORE USE, Orange Cap
Recipients and Caregivers Fact Sheet (5 through 11 years of age)


Before administration of Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), please click to see
EUA Fact Sheet for Vaccination Providers, Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) (Booster Dose 12 years of age and older), DO NOT DILUTE, Gray Cap
Recipients and Caregivers Fact Sheet: (Primary Series and Bivalent Booster Dose 12 years of age and older)


Before administration of Pfizer-BioNTech COVID-19 Vaccine or COMIRNATY (COVID-19 Vaccine, mRNA), please click to see
Full Prescribing Information (Primary Series 12 years of age and older), DO NOT DILUTE, Gray Cap
Full Prescribing Information (Primary Series 12 years of age and older), DILUTE BEFORE USE, Purple Cap
EUA Fact Sheet for Vaccination Providers (Primary Series 12 years of age and older), DO NOT DILUTE, Gray Cap
EUA Fact Sheet for Vaccination Providers (Primary Series 12 years of age and older), DILUTE BEFORE USE, Purple Cap
Recipients and Caregivers Fact Sheet: (Primary Series and Bivalent Booster Dose 12 years of age and older)


For More Information

Medical Information Medical Information

Medical Information

Visit PfizerMedicalInformation.com
or call 1-800-438-1985

General Product Inquiries General Product Inquiries

General Product Inquiries

Call 1-877-829-2619

Shipment Support US Trade Customer Service Shipment Support US Trade Customer Service

Shipment Support
US Trade Customer Service

Call 1-800-666-7248

Pfizer Customer Service Pfizer Customer Service

Pfizer Customer Service

Call 1-800-879-3477

Now Authorized: Effective 08/31/22

PFIZER-BIONTECH COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5) IS NOW AUTHORIZED FOR EMERGENCY USE AS A SINGLE BOOSTER DOSE IN ELIGIBLE INDIVIDUALS 12 YEARS OF AGE AND OLDER

Click to view the newly authorized EUA Fact Sheet for Vaccination Providers, Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) (Booster Dose 12 years of age and older), DO NOT DILUTE, Gray Cap

Emergency Use Authorization

Emergency uses of Pfizer-BioNTech COVID-19 Vaccine, Bivalent have not been approved or licensed by FDA but have been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) in individuals aged 12 years and older. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.

Authorized Use

Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older.

This EUA Prescribing Information pertains only to Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), hereafter referred to as Pfizer-BioNTech COVID-19 Vaccine, Bivalent.

Vaccination Schedule

A single booster dose (0.3 mL) of Pfizer-BioNTech COVID-19 Vaccine, Bivalent may be administered at least 2 months after completion of primary vaccination or receipt of the most recent booster dose with any authorized or approved monovalent* COVID-19 vaccine.

*Monovalent refers to any authorized or approved COVID-19 vaccine that contains or encodes the spike protein of only the Original SARS-CoV-2.

Selected Safety Information

Do not administer Pfizer-BioNTech COVID-19 Vaccine, Bivalent to individuals with known history of a severe allergic reaction (eg, anaphylaxis) to any component of Pfizer-BioNTech COVID-19 Vaccine or Pfizer-BioNTech COVID-19 Vaccine, Bivalent.

Management of Acute Allergic Reactions

Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer-BioNTech COVID-19 Vaccine, Bivalent.

Monitor vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html).

Myocarditis and Pericarditis

Myocarditis and pericarditis have been reported following administration of Pfizer-BioNTech COVID-19 Vaccine.

Postmarketing safety data with Pfizer-BioNTech COVID-19 Vaccine are relevant to Pfizer-BioNTech COVID-19 Vaccine, Bivalent because these vaccines are manufactured using the same process.

Postmarketing data with authorized or approved monovalent mRNA COVID-19 vaccines demonstrate increased risks of myocarditis and pericarditis, particularly within the first week following receipt of the second primary series dose or first booster dose, with most booster doses likely administered at least 5 months after completing primary vaccination. For the Pfizer-BioNTech COVID-19 Vaccine, the observed risk is higher among adolescent males and adult males under 40 years of age than among females and older males, and the observed risk is highest in males 12 through 17 years of age. Although some cases required intensive care support, available data from short-term follow-up suggest that most individuals have had resolution of symptoms with conservative management. Information is not yet available about potential long-term sequelae. The CDC has published considerations related to myocarditis and pericarditis after vaccination, including for vaccination of individuals with a history of myocarditis or pericarditis (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html).


Verify the vials (including labels) prior to preparation and administration to help avoid dosing errors. Check gray cap vial label to ensure that the name on the vial states “Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5).” Please see the Formulation/Presentation Guide for more details.

Formulation/
Presentation Guide
Select FAQs

Regardless of storage condition, the vaccine should not be used after 12 months from the date of manufacture printed on the vials and cartons.

I acknowledge that this website is being updated on an ongoing basis. I have read the Important Safety Information. I will check back for further updates.

Continue
Scroll down to continue